After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.
Four top stocks have at least a 4% dividend and make sense for investors who may be worried about increased volatility in the ...
The approval of etanercept for juvenile idiopathic arthritis in 1999 heralded a new era for children with arthritis. However, ...
Half of all pancreatic cancer patients live less than a year after diagnosis. But researchers say there is potential for ...
Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and ...
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
Oppenheimer & Co. Inc. reduced its stake in Bristol-Myers Squibb by 8.1%, selling nearly 19,000 shares in Q4. The ...
In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...
From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...
Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.
Cash, cash equivalents and marketable securities totaled approximately $1.5 billion as of December 31, 2024. Collaboration revenues of $3.0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results